IP Library › Granted Patent US 10,993,990
Granted Patent B2
US 10,993,990 · App. 15/311,572 · Granted May 4, 2021

Methods and compositions for treating autoimmune and inflammatory conditions

Inventors: SangKon Oh (Baltimore, MD); Sandra Zurawski (Midlothian, TX); Hyemee Joo (Dallas, TX); Gerard Zurawski (Midlothian, TX)
Assignee: Baylor Research Institute
A61K38/2066A61K39/0008C07K14/5428C07K16/2851C07K16/2878A61K2039/505A61K2039/54A61K2039/57C07K2317/24C07K2317/40C07K2317/52C07K2317/53C07K2317/56C07K2317/565C07K2317/73C07K2317/75C07K2319/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,993,990
App. No.
15/311,572
Granted
May 4, 2021
Kind
B2
Abstract

Described herein are compositions and methods for inhibiting an inflammatory or autoimmune response and for inducing immune tolerance in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an antigen presenting cell (APC)-targeted antibody operatively linked to IL-10 or a fragment thereof. The compositions and methods described herein are useful for treating inflammatory and autoimmune disorders.

Claims (7)

1. A method for preventing or treating graft versus host disease (GVHD) in a subject in need thereof comprising administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of an anti-DC-ASGPR antibody or antigen binding fragment thereof operatively linked to IL-10; wherein the pharmaceutical composition does not comprise an antigen associated with an autoimmune disease or inflammatory condition.

2. The method of claim 1 , wherein the anti-DC-ASGPR antibody or antigen binding fragment thereof comprises three heavy chain CDRs and three light chain CDRs from the variable regions of an anti-DC-ASGPR heavy chain and light chain variable region pair selected from SEQ ID NO:3 and 8; SEQ ID NO:58 and 60; SEQ ID NO:62 and 64; or SEQ ID NO:66 and 68.

3. The method of claim 1 , wherein the anti-DC-ASGPR antibody or antigen binding fragment thereof comprises a γ4 constant region comprising a substitution of glutamic acid at residue 235 and/or a substitution of proline at residue 228 in the hinge region.

4. The method of claim 1 , wherein the subject has been diagnosed as having GVHD.

5. The method of claim 1 , wherein the subject is one that will receive or has received transplanted tissue.

6. The method of claim 1 , wherein the method comprises administering to the subject an anti-DC-ASGPR antibody.

7. The method of claim 1 , wherein the anti-DC-ASGPR antibody or antigen binding fragment thereof is administered intravenously.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 13, 2016
From: OH, SANGKON; ZURAWSKI, SANDRA; JOO, HYEMEE; ZURAWSKI, GERARD
To: BAYLOR RESEARCH INSTITUTE
Reel/Frame 040718/0544 →
Continuity (3)
Provisional Application 61994239 · May 16, 2014
Provisional Application 62014504 · Jun 19, 2014
Related Publication 20170106051A1 · Apr 20, 2017